azd-4877
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT00389389)
Timeline
Indications
Mechanism of action
- Kinesin-like protein 1INHIBITOR
KIF11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1- Mol. weight
- 503.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1829433 ↗
Also known as
- azd4877
- azd4877
- azd4877
- azd 4877
- azd-4877
- azd-4877
- n-(3-aminopropyl)-n-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00661609 | Phase 2 | May 1, 2008 | AstraZeneca, Temple University |
| NCT00613652 | Phase 1 | Jan 1, 2008 | AstraZeneca |
| NCT00486265 | Phase 1 | Jul 1, 2007 | AstraZeneca |
| NCT00471367 | Phase 1 | Apr 1, 2007 | AstraZeneca |
| NCT00460460 | Phase 1 | Mar 1, 2007 | AstraZeneca |
| NCT00389389 | Phase 1 | Sep 1, 2006 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 6 | 6 | 2 | 2006 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1